Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajim.23554 | DOI Listing |
Front Immunol
January 2025
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.
Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.
iScience
October 2024
National Centre for Asbestos Related Diseases, University of Western Australia, Nedlands, WA, Australia.
Mesothelioma is a lethal cancer. Despite promising outcomes associated with immunotherapy, durable responses remain restricted to a minority of patients, highlighting the need for improved strategies that better predict outcome. Here, we described the development of a mesothelioma-specific gene signature that accurately predicts survival.
View Article and Find Full Text PDFCytojournal
September 2024
Department of Pathology, The Johns Hopkins Hospital, Baltimore, United States.
Lung Cancer
November 2024
Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:
Pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. In particular, the frequent loss of tumor suppressors, a key oncogenic driver of the disease that is therapeutically intractable, has hampered the development of targeted cancer therapies. Here, we interrogate the PM genome using CRISPR-mediated gene editing to systematically uncover PM cell susceptibilities and provide an evidence-based rationale for targeted cancer drug discovery.
View Article and Find Full Text PDFJ Surg Oncol
September 2024
Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Lyon, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!